CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
The new online Learning Center with new content can still be found under the “Training” folder on ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...